Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Current Liabilities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Total Current Liabilities for 7 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 50.73% to $16.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.4 million, a 50.73% decrease, with the full-year FY2025 number at $16.4 million, down 50.73% from a year prior.
  • Total Current Liabilities was $16.4 million for Q4 2025 at Pliant Therapeutics, down from $17.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $40.0 million in Q3 2024 to a low of $10.2 million in Q1 2021.
  • A 5-year average of $23.4 million and a median of $23.5 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 106.3% in 2022, then crashed 55.89% in 2025.
  • Pliant Therapeutics' Total Current Liabilities stood at $16.8 million in 2021, then surged by 42.08% to $23.9 million in 2022, then increased by 19.28% to $28.5 million in 2023, then rose by 16.46% to $33.2 million in 2024, then tumbled by 50.73% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Total Current Liabilities are $16.4 million (Q4 2025), $17.6 million (Q3 2025), and $20.6 million (Q2 2025).